Association of the Non-HDL-cholesterol to HDL-cholesterol Rate and the Risk of Non-alcoholic Fatty Liver Disease Among Children and Adolescence: A Retrospective Cohort Study

Shouxing Yang
Zhuji People's Hospital of Zhejiang Province  https://orcid.org/0000-0002-9545-6849

Jinwei Zhong
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Mengsi Ye
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Le Miao
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Guangrong Lu
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Changlong Xu
The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Zhanxiong Xue
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Xinhe Zhou (✉ 2206251@qq.com)
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Research

Keywords: non-HDL-c/HDL-c rate, Non-alcoholic fatty liver disease, children, adolescence, cohort study

DOI: https://doi.org/10.21203/rs.3.rs-63438/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The non-HDL-cholesterol to HDL-cholesterol (non-HDL-c/HDL-c) rate shows a close relationship to multiple dyslipidemia related disease. This paper aims at investigating the association of the non-HDL-c/HDL-c rate and the risk of NAFLD among children and adolescence in China.

**Methods:** In this retrospective cohort study, a total of 7759 eligible children and adolescence (5692 boys, 2067 girls) having received regular medical examination were recruited. We collected anthropometric measurements and laboratory tests data of subjects. The binary logistics regression was employed for the assessment of the associations of the non-HDL-c/HDL-c rate with NAFLD. Sex-specific ROC curve analysis was conducted for comparing the predictive value of non-HDL-c/HDL-c rate, non-HDL-c and HDL-c for NAFLD.

**Results:** The total NAFLD prevalence was 4.36%, higher in boys than that in girls (5.61% vs. 1.9%, \( P < 0.001 \)). It is noteworthy that NAFLD prevalence displayed positive correlation with the non-HDL-c/HDL-c rate (Chi-square test, \( P < 0.001 \)). The binary logistics regression analysis shows that the OR were 8.61 (95% CI = 5.90-12.57, \( P < 0.001 \)) in the maximum tertiles (maximum non-HDLc/HDLc ratio) compared with the minimum tertiles. When potential confounders were regulated, compared with the minimum tertiles, the OR for the maximum tertiles (OR=3.94, 95%CI=2.33-6.66, \( P < 0.001 \)) was still significantly higher. AUC values of the non-HDL-c/HDL-c rate (0.787 in boys and 0.763 in girls) noticeably reached over non-HDL-c (0.719 in boys and 0.661 in girls) and HDL-c (0.726 in boys and 0.732 in girls). Furthermore, the optimal cutoff value of the non-HDL-c/HDL-c rate for NAFLD was 2.475 in boys and 2.695 in girls.

**Conclusions:** The present study indicate that a higher non-HDL-c/ HDL-c rate caused a higher risk of NAFLD among children and adolescence. Moreover, the non-HDL-c/HDL-c rate showed a better predictive value for NAFLD than the non-HDL-c and HDL-c in both boys and girls.

Background

Non-alcoholic fatty liver disease (NAFLD) refers to a chronic liver disease, involving fatty liver or hepatic steatosis, as well as nonalcoholic steatohepatitis (NASH)[1]. Nowadays, NAFLD is shifting to the most frequent reason for chronic liver disease in pediatric population. Given epidemiological data, NAFLD prevalence is 2.6–7.1% of all children and about 27.8–41.2% of obese children. Furthermore, the incidence rate of NAFLD is on the rise[2] [3].

NAFLD is now recognized as a metabolic syndrome manifested in hepatic area, and its progressive form NASH elevating the risk of liver cancer, end-stage liver disease and cirrhosis[4]. Furthermore, Pediatric NAFLD is considered to be related to the pathogenesis of cardiovascular disease, metabolic syndrome and diabetes mellitus[5]. Since children with NAFLD are usually symptomless, it is challenging to diagnosis of NAFLD among pediatric population. Liver biopsy is known as the gold standard for NAFLD diagnosis, whereas it is not readily accepted by children as its invasive nature. Liver ultrasonography refers to a feasible and noninvasive mean to diagnose NAFLD, whereas not all children undergo liver
ultrasonography since their parents may be reluctant to let them receive medical examination for a clinically silent disease[6]. Thus, valuable predictors for NAFLD should be identified for early detection and prevention of later progression.

Non-high-density lipoprotein cholesterol (non-HDL-c), which refers to total cholesterol (TC) minus high-density lipoprotein cholesterol (HDL-c), is regarded as secondary target of lipid-lowering therapeutic method. Several studies reported that the non-HDL-c/HDL-c rate displays close relationships to multiple dyslipidemia-related disease. A Prospective study form UK reported the non-HDL-c/HDL-c rate can more significantly predict coronary heart disease in type 2 diabetes than non-HDL-c[7]. Moreover, The non-HDL-c/HDL-c rate is an independent risk factor of chronic kidney disease and gallbladder polyp, and it is an ideal marker for insulin resistance and metabolic syndrome[8–10]. As revealed from a perspective cohort study, non-HDL-c/HDL-c rate can more noticeably predict new-onset NAFLD than Non-HDL-c among adults[11]. However, the association between the non-HDL-c/HDL-c ratio and NAFLD among pediatric population remains unknown. Therefore, this retrospective study aims at exploring the association of the non-HDL-c/HDL-c rate and the risk of NAFLD among Chinese children and adolescence.

Materials And Methods

Subject

7759 children and adolescence (age 2–18 years) having received regular medical examination from January 2015 to January 2020 in the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University were retrospectively reviewed. Exclusion criteria were metabolic liver disease, hepatitis B virus or hepatitis c virus infection, Wilson's disease, medication use in the past 1 months, hereditary hyperlipidemia and alcohol consumption.

Anthropometric measurements and laboratory tests

The clinical and anthropometric measurements assessed were age, gender, weight and height. Height and weight were tested on the same day, which were nearest 0.01 kg and 0.01 m. BMI was weight (kg) divided by height squared (m$^2$). Children referred to obesity if their BMI above 95th percentile[12]. As for laboratory test, under standard laboratory procedures, this study employed fasting blood samples to delve into metabolic variables. This study collected the parameters, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), total cholesterol (TC), albumin(ALB), uric acid (UA), glycosylated hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG). By the Homeostasis Model Assessment of IR (HOMA-IR), insulin resistance (IR) was determined. By the Quantitative Insulin-sensitivity Check Index (QUICKI), this study conducted the evaluation of insulin-sensitivity (IS). HOMA-IR index and QUICKI were calculated by: HOMA-IR = fasting insulin (U/mL) × fasting glucose (mg/dL)/405, QUICKI = 1/[log fasting insulin(U/ml) + log fasting glucose (mg/dl)][13].

Ultrasonography
Liver ultrasonography was performed by an experienced expert with a Philips Envisor26 type ultrasonic diagnostic instrument (probe frequency 3.5-5.0 MHz). The NAFLD was diagnosed based on the following radiologic parameters: deep attenuation of ultrasound signal, vascular blurring, and diffusely increased echogenicity (bright) liver exhibiting liver echogenicity over kidney or spleen[14].

**Statistical analysis**

All data were analyzed by SAS version 9.3 (SAS Institute, Cary, NC). Means ± standard deviations denoted continuous data, and categorical variables were expressed as percentages. For the assessment of the difference in groups, this study performed independent sample t-test for continuous variables with normal distribution and Chi-square test for categorical data. The binary logistics regression was applied to assess odds rates (OR) and 95% confidence intervals (CI) in terms of the relationships of the non-HDL-c/HDL-c rate and NAFLD. For the assessment of the utility of different lipid levels as predictors for NAFLD, sex-specific receiver operating characteristic (ROC) curve was plotted for the cut-off level of the non-HDL-c/HDL-c rate to predict NAFLD. $P<0.05$ was considered exhibiting statistical significance. Figures here were generated by Graphpad prism 6 project.

**Results**

**Baseline characteristics**

This study recruited a total of 7759 eligible children and adolescence (5692 boys, 2067 girls). Table 1 draws the comparison of the baseline characteristics of participants by tertiles of the non-HDL-c/HDL-c rate. Significant differences were identified in the three groups. In contrast to subjects in the maximum tertile of the non-HDL-c/HDL-c rate, those in the minimum tertile were had lower ALT, UA, ALB, TC, TG, LDL, HBA1C(%), FBG, HOMA-IR and higher HDL and QUICKI ($P<0.001$). The incidence of obesity noticeably rose across non-HDL-c/HDL-c tertiles (4.81% vs. 9.22% vs. 21.18%, for tertile 1 vs. tertile 2 vs. tertile 3, respectively, $P<0.001$).
Table 1
Baseline characteristics by tertiles of the non-HDL-c/HDL-c rate

| characteristics                | non-HDL-c/HDL-c ratio |       |       |       |       |
|-------------------------------|-----------------------|-------|-------|-------|-------|
|                               | Tertile 1             | Tertile 2 | Tertile 3 |       |       |
|                               | (≤ 1.79)              | (1.80–2.36) | (≥ 2.37) |       |       |
| Sample size                   | 2577                  | 2580   | 2602   |       |       |
| Age (year)                    | 9.24 ± 3.11           | 9.00 ± 3.31 | 9.03 ± 3.47 | 0.017 |       |
| Sex, n (%)                    | < 0.001               | < 0.001 | < 0.001 |       |       |
| Girl                          | 771 (29.92)           | 950 (36.82) | 906 (34.82) |       |       |
| Boy                           | 1806 (70.08)          | 1630 (63.18) | 1696 (65.18) |       |       |
| ALT (U/L)                     | 15.12 ± 8.49          | 15.93 ± 17.55 | 19.27 ± 19.88 | < 0.001 |       |
| AST (U/L)                     | 26.51 ± 6.75          | 26.64 ± 13.29 | 27.09 ± 13.62 | 0.175 |       |
| Uric acid (umol/L)            | 300.55 ± 69.92        | 305.06 ± 73.84 | 327.42 ± 85.44 | < 0.001 |       |
| Albumin (g/L)                 | 45.36 ± 2.22          | 45.48 ± 2.17 | 45.78 ± 2.33 | < 0.001 |       |
| Total cholesterol (mmol/L)    | 4.09 ± 0.63           | 4.27 ± 0.65 | 4.62 ± 0.82 | < 0.001 |       |
| Triglycerides (mmol/L)        | 0.77 ± 0.30           | 0.89 ± 0.36 | 1.21 ± 0.64 | < 0.001 |       |
| HDL-c (mmol/L)                | 1.67 ± 0.29           | 1.39 ± 0.22 | 1.17 ± 0.21 | < 0.001 |       |
| LDL-c (mmol/L)                | 1.90 ± 0.45           | 2.31 ± 0.46 | 2.79 ± 0.67 | < 0.001 |       |
| HBA1C (%)                     | 5.43 ± 0.29           | 5.43 ± 0.27 | 5.46 ± 0.29 | 0.001  |       |
| Fasting plasma glucose (mmol/L)| 4.68 ± 0.39           | 4.70 ± 0.38 | 4.73 ± 0.37 | < 0.001 |       |
| HOMA-IR                       | 1.42 ± 1.28           | 1.67 ± 1.93 | 2.16 ± 2.07 | < 0.001 |       |
| QUICK                         | 0.76 ± 0.18           | 0.73 ± 0.17 | 0.68 ± 0.17 | < 0.001 |       |
| Percentage of obesity(N[%])  | 124 (4.81%)           | 238 (9.22%) | 551 (21.18%) | < 0.001 |       |

Data are expressed as the mean ± SD or percentage

ALT Alanine aminotransferase; AST Aspartate aminotransferase; IDL-c low-density lipoprotein cholesterol; HDL-c High-density lipoprotein cholesterol; HbA1c Glycosylated hemoglobin A1c; HOMA-IR Homeostasis Model Assessment of IR; QUICKI Quantitative Insulin-sensitivity Check Index

Children referred to obesity if their BMI above 95th percentile

NAFLD prevalence and the rise of the non-HDL-c/HDL-c rate

NAFLD prevalence showed positively correlation with the non-HDL-c/HDL-c rate. The proportion of subjects who had NAFLD in tertile 2 (2.33%, P < 0.001) and tertile 3 (9.49%, P < 0.001) was significantly

Page 5/14
higher than that in tertile 1 (1.2%). NAFLD prevalence in tertile 3 was nearly eight time larger compared with that of tertile 1. (Fig. 1)

**Gender specific differences on the prevalence of pediatric NAFLD**

The overall NAFLD prevalence was 4.36%. It is noteworthy that NAFLD prevalence in boy was higher than that in girl. (5.61% vs. 1.9%, \( P < 0.001 \)) (Fig. 2).

**Association between the non-HDL-c/HDL-c rate and the incidence of NAFLD in children and adolescence**

Table 2 lists the results of the binary logistics regression analysis. The OR for NAFLD was significantly elevated as the tertiles of non-HDL-c/HDL-c rate arose. For a function of the tertiles of non-HDL-c/HDL-c rate, the OR for NAFLD was 8.61 (95% CI = 5.90-12.57, \( P < 0.001 \)) in children and adolescence, in the maximum tertiles compared with the minimum tertiles. Further adjustment of age, sex, ALT, UA, ALB, FBG, HOMA-IR exerted no effect on this association. In comparison with tertile 1, the OR for tertile 3 (OR = 3.94, 95%CI = 2.33–6.66, \( P < 0.001 \)) was still significantly higher. Moreover, 0.9 µmol/L increase in the non-HDL-c/HDL-c rate showed associations with 2.70 fold larger danger of getting NAFLD (OR = 2.70, 95%CI = 2.19–3.34, \( P < 0.001 \)). As revealed from the mentioned findings, higher non-HDL-c/HDL-c ratio was highly positively associated with an increased risk of NAFLD among children and adolescence.

| Non-HDL-c/HDL-c ratio | N   | Cases (%) | Crude          | Adjusted*          |        |        |
|-----------------------|-----|-----------|----------------|--------------------|-------|-------|
|                       |     |           | OR(95% CI)     | \( P \)            | OR(95% CI) | \( P \) |
| Category variable     |     |           |                |                    |       |       |
| Tertile 1 (\( \leq 1.79 \)) | 2577 | 31 (1.20) | 1.0(1.0,1.0)    | Ref.               | 1.0(1.0,1.0) | Ref.  |
| Tertile 2(1.80–2.36)  | 2580 | 60 (2.33) | 1.96(1.16,3.03) | 0.002              | 1.56(0.85,2.85) | 0.014 |
| Tertile 3 (\( \geq 2.37 \)) | 2602 | 247 (9.49) | 8.61(5.90,12.57) | 0.000              | 3.94(2.33,6.66) | 0.000 |
| Continuous variable   |     |           |                |                    |       |       |
| Per IQR(= 0.9)        | 7759 | 338(4.34) | 3.24(2.87,3.66) | 0.000              | 2.70(2.19,3.34) | 0.000 |

Data are odds rates (OR) and 95% confidence intervals (CI), \( P \) value

HDL-c High-density lipoprotein cholesterol

Adjusted* for age, sex, alanine aminotransferase, uric acid, albumin, fasting plasma glucose, HOMA-IR
The predictive value of the non-HDL-c/HDL-c rate for NAFLD risk

To compare the predictive value of non-HDL-c/HDL-c rate, non-HDL-c and HDL-c for NAFLD, this study conducted the sex-specific receiver operating characteristic (ROC) curve analyses (Fig. 3). The area under the curves (AUCs) of the non-HDL-c/HDL-c rate (AUC = 0.787, 95% CI = 0.758–0.816 in boys and AUC = 0.763, 95% CI = 0.688–0.837 in girls) noticeably reached over those of non-HDL-c (AUC = 0.719, 95% CI = 0.687–0.751 in boys and AUC = 0.661, 95% CI = 0.580–0.743 in girls) and those of HDL-c (AUC = 0.726, 95% CI = 0.698–0.755 in boys and AUC = 0.732, 95% CI = 0.663–0.802 in girls). Furthermore, the optimal cutoff value of the non-HDL-c/HDL-c rate for NAFLD in boys was 2.475, exhibiting a sensitivity of 71.18% and a specificity of 74.46%; besides, the cutoff value in girls was 2.695, exhibiting a sensitivity of 66% as well as a specificity of 80.09%.

Discussion

In the present retrospective cohort study, we found for first time that a higher non-HDL-c/HDL-c rate had a higher risk of NAFLD among children and adolescence. It is noteworthy that the mentioned relationship lasted when potential confounders were regulated. Moreover, the non-HDL-c/HDL-c rate a better predictive value for NAFLD than the non-HDL-c and HDL-c in both boys and girls. The findings of this study suggested that the non-HDL-c/HDL-c ratio may help early identify NALFD among children and adolescents.

Previous studies had confirmed that metabolic syndrome (MetS) and obesity are the major risk factors for paediatric NAFLD and dyslipidemia play a pivotal role in NAFLD pathogenesis[4, 15]. Recent clinical trials suggest that statin-based therapies (lipid-lowering drug statin treatment) could improve liver tests and live ultrasonographic evidence of NAFLD patients[16]. The dyslipidemia in NAFLD is characterized by elevated conditions of TG and dense low-density lipoprotein (LDL) particles and decreased conditions of low high-density lipoprotein (HDL) cholesterol[17]. In NAFLD, as driven by lipid metabolism abnormalities, excess fat undergoes accumulation in the hepatocytes. The mentioned intrahepatic lipid accumulating was attributed to decreased triglycerides (TG) export and significantly low density lipoprotein (VLDL) synthesis as well as liver free fatty acid (FFA) uptake [18, 19]. Ectopic lipid overloading in hepatocytes are associated with an induction of inflammation and oxidative stress, and the secreting of several cytokines (including adiponectin, interleukins (ILs) and tumor necrosis factor (TNF)) [20]. Moreover, excess of FFAs form to fatty acyl-CoAs catalyzed by acetyl coenzyme A (acyl-CoA), thereby probably inducing β-oxidation pathways. The above inflammation, oxidative stress are involved in NAFLD initiation and progression [21, 22].

Non-HDL-c contains multiple lipoproteins(lipoprotein A, intermediate-density lipoprotein (IDL), low density lipoprotein (LDL) and very-low-density lipoprotein (VLDL)) and was demonstrated as a secondary targets for lipid-lowering therapy[23]. In comparison with the non-HDL-c, the non-HDL-c/HDL-c rate can cover more comprehensive abilities of lipid dysregulation and better for assessing lipid-related disease risk.
Existing studies reported that non-HDL-c/HDL-c rate more effectively predicts CVD in type 2 diabetes than non-HDL-c[11], and the ratio exhibits higher predictive value than the apoB/apoA1 rate in terms of insulin resistance and MS[8]. Moreover, as revealed from a perspective cohort study, non-HDL-c/HDL-c rate outperforms non-HDL-c in predicting new-onset NAFLD in Chinese adult population[11]. Thus, the associations of the non-HDL-c/HDL-c rate and the risk of NAFLD among children and adolescence should be explored.

Dividing the baseline characteristical data of 7759 participants into tertiles according to non-HDL-c/HDL-c ratio, we found anthropometric variables such as ALT, TG, LDL, HBA1C(%), FBG were higher in the highest tertile than the lowest one. The similar results can be found in previous studies[24]. As expected, the incidence of obesity significantly increased across non-HDL-c/HDL-c tertiles. In addition, the prevalence of NAFLD increased as the tertiles of the non-HDL-c/HDL-c ratio rose. The binary logistics regression analysis suggested that higher non-HDL-c/HDL-c ratio was highly positively associated with an increased risk of NAFLD. In terms of gender distribution, Our study found the prevalence of NAFLD by gender was significant higher in boys compared to girls. The result of this study complies with Brunt EM et al.[25] and Welsh JA et al.[26], demonstrating that boys are more likely to develop NAFLD than girls. It has been indicated this phenomenon may be attributed to the potential protective role of estrogen against hepatic steatosis[27, 28].

The findings here are of certain clinical implications. We performed ROC curve analyses to explore the predictive value of the non-HDL-c/HDL-c ratio for NAFLD risk. Our findings suggest that the non-HDL-c/HDL-c ratio may serve as a more effective predictor for pediatric NAFLD than non-HDL-c and HDL-c. The optimal cutoff values of the non-HDL-c/HDL-c rate to identify NAFLD was 2.475 in boys and 2.695 in girls. Besides, the non-HDL-c/HDL-c rate exhibits simplicity and feasibility to determine. Accordingly, the non-HDL-c/HDL-c rate might feasibly achieve prediction and be used for screening for NALFD among children and adolescents.

Some limits are worth noting here. First, the diagnosis of NAFLD was performed using ultrasonography instead of liver biopsy (gold standard for diagnosing NAFLD) which is limited for its complications and invasiveness. However, the sensitivity of ultrasonography is low when NAFLD with fat contents less than 30%, thereby probably causing misdiagnosis[29]. Second, since this was a single center cohort study, largescale and multiple center studies should be conducted to confirm our conclusions of the present study. Third, this study had a retrospectively designing process, so the causality between non-HDL-c/HDL-c rate and NAFLD is not able to be overall set. The association requires confirmation by prospective retrospective study.

**Conclusions**

To sum up, as proved by the results of this study, a higher non-HDL-c/ HDL-c rate had a higher risk of NAFLD among children and adolescence for the first time. Moreover, the non-HDL-c/HDL-c rate showed a better predictive value for NAFLD than the non-HDL-c and HDL-c borth in boys and girls, which is simple
and feasible to get by calculating from traditional lipid measures. For the mentioned reason, the non-HDL-c/HDL-c rate may be an effective predictor to detect individuals at risk of NAFLD and facilitate the prevention of the disease progression and favor long-term outcomes.

**Abbreviations**

NAFLD: Non-alcoholic fatty liver disease; Non-HDL-c/HDL-c: Non-HDL-cholesterol to HDL-cholesterol; NASH: Nonalcoholic steatohepatitis; Non-HDL-c: Non-high-density lipoprotein cholesterol; TC: Total cholesterol; HDL-c: High-density lipoprotein cholesterol; AST: Aminotransferase; ALT: Alanine aminotransferase; LDL: Low-density; HDL: High-density lipoprotein; TG: Triglycerides; ALB: Albumin; UA: Uric acid; FPG: Fast plasma glucose; HOMA-IR: Homeostasis Model Assessment of IR; QUICKI: Quantitative Insulin-sensitivity Check Index; OR: Odds rate; CI: Confidence intervals; ROC: Receiver operating characteristic; AUC: Area under the curve

**Declarations**

**Acknowledgements**

Great thanks to Xinhe Zhou (Department of Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University) for her helpful comments of the study.

**Authors’ contributions**

SXY and XHZ designed the study and wrote the manuscript; MSY, GRL, LM and JWZ collected anthropometric measurements and laboratory tests data, XZX analysed the data. All authors approved the final manuscript.

**Funding**

**Availability of data and materials**

All data used in this study are available from the corresponding Author.

**Ethics approval and consent to participate**

This retrospective study protocol obtained the approving documents from the Ethics Committee of the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. All children's parents provided informed consent.

**Consent for publication**

Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

References

1. Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K: Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care 2016, 39:632-638.

2. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V: Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012, 9:152-161.

3. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A: The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10:e0140908.

4. Katsiki N, Mikhailidis DP, Mantzoros CS: Non-alcoholic fatty liver disease and dyslipidemia: An update. Metab. Clin. Exp. 2016, 65:1109-1123.

5. Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, Raponi M, Dhawan A: Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015, 169:170-176.

6. Kim JY, Cho J, Yang HR: Biochemical Predictors of Early Onset Non-Alcoholic Fatty Liver Disease in Young Children with Obesity. J. Korean Med. Sci. 2018, 33:e122.

7. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23.

8. Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC, Kim SW, Chung JH, Min YK, Lee MS, et al: Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int. J. Cardiol. 2013, 168:2678-2683.

9. Zuo PY, Chen XL, Liu YW, Zhang R, He XX, Liu CY: Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease. Nutr Metab Cardiovasc Dis 2015, 25:582-587.

10. Zhao X, Zheng H, Shan S, Wang K, Zhang M, Xie S, Liu C: Association between the non-HDL-cholesterol-to-HDL-cholesterol ratio and the risk of gallbladder polyp formation among men: a retrospective cohort study. Lipids Health Dis 2020, 19:146.

11. Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C: Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis 2018, 17:196.

12. Flegal KM, Cole TJ: Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. Natl Health Stat Report 2013 ;1-3.

13. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000, 85:2402-2410.
14. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on NAFLD: Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007, 22:775-777.

15. Fang YL, Chen H, Wang CL, Liang L: Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". World J. Gastroenterol. 2018, 24:2974-2983.

16. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP: Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone. Ann. Med. 2011, 43:167-171.

17. Chatrath H, Vuppalanchi R, Chalasani N: Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver Dis. 2012, 32:22-29.

18. Musso G, Gambino R, Cassader M: Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52:175-191.

19. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS: Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016, 59:30-43.

20. Reddy JK, Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G852-858.

21. Ferramosca A, Zara V: Modulation of hepatic steatosis by dietary fatty acids. World J. Gastroenterol. 2014, 20:1746-1755.

22. Mashek DG, Khan SA, Sathyanarayan A, Ploeger JM, Franklin MP: Hepatic lipid droplet biology: Getting to the root of fatty liver. Hepatology 2015, 62:964-967.

23. Expert Panel on Detection, Evaluation, Adults aToHBCi: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.

24. Wang D, Wang L, Wang Z, Chen S, Ni Y, Jiang D: Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis. Lipids Health Dis 2018, 17:67.

25. Brunt EM: Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:195-203.

26. Welsh JA, Karpen S, Vos MB: Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J. Pediatr. 2013, 162:496-500.e1.

27. Liu Z, Que S, Zhou L, Zheng S: Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. Sci Rep 2015, 5:14325.

28. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A: NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther 2017, 34:1291-1326.
29. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002, 123:745-750.

Figures

**Figure 1**

The prevalence of NAFLD according to the non-HDL-c/HDL-c ratio tertiles.
Figure 2

Gender specific differences on the prevalence of pediatric NAFLD

AUC
- Non-HDL-c/HDL-c=0.787
- Non-HDL-c=0.719
- HDL-c=0.726

AUC
- Non-HDL-c/HDL-c=0.783
- Non-HDL-c=0.661
- HDL-c=0.732
Figure 3

Receiver operating characteristic curve of non-HDL-c/HDL-c ratio, HDL-c and non-HDL-c for NAFLD in boys (A) and girls (B)